Slide 1: Genscript Biotech Corporation Company Presentation
Genscript Biotech Corporation Company Presentation （Stock Code：1548.HK）
Slide 2: Disclaimer
Disclaimer NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS NOT PERMITTED UNDER THE LAW OF THAT JURISDICTION. This document has been prepared by Genscript Biotech Corporation (the “Company”) for a limited number
Slide 3: Agenda: Company Overview
Company Overview Financial & Business Overview Future Strategy Q&A Section Appendix 3
Slide 4: Mission
Mission Make People and Nature Healthier through Biotechnology Make Research Easy Make the Best Enzyme Bring Miracles to Life 4
Slide 5: History & Milestone
History & Milestone 2018 • Merged Nornoon Company • New Nanjing research and production • Launched the Cell Therapy Segment facility opened • Selected as the sole business entity to • CRO Leadership award 2017 • MM Program received IND approval in US and • Introduced Custom participate in the Synthe
Slide 6: Business Blueprint
Business Blueprint CAR T-Cell Industrial Immunotherapy enzymes Life sciences research and application services and products Gene synthesis New Area of Business Development Generating Higher Return Core Business Generating Cash Flow for Future Development Genscript Proprietary Technologies
Slide 7: Strategic Business Positioning
Strategic Business Positioning Life Science CRO CDMO Platform Make Research Easier through innovative and Accelerate drug discovery and development productive life science services and products Process through advanced platform technology and solutions Innovative Technologies Drive Sustainable Growt
Slide 8: Company Overview
Company Overview Positioning Customers • Largest provider of gene synthesis services globally; • 5,000+ customers which includes global • Global provider of life sciences research and application pharmaceutical and biotech companies, colleges and services and products; universities, research institu
Slide 9: Agenda: Financial & Business Overview
Company Overview Financial & Business Overview Future Strategy Q&A Section Appendix 9
Slide 10: Financial Performance
Financial Performance 1H 2018 1H 2017 % Change (US$MM) (US$MM) Achieved strong revenue YoY growth of 77.0%; Revenue 112.2 63.4 77.0% Stable gross margin ratio that maintained above 70%; Gross Profit 81.4 42.9 89.7% Core services (bio-science research services and products) maintained market le
Slide 11: Revenue Analysis-Segment Performance
Revenue Analysis-Segment Performance Revenue by Business Segment Segment Revenue Contribution 27% 112.2 6% 74.6 67% 63.4 58.7 30.4 7.2 4.7 0 Total Revenue Bio-science Services and Cell Therapy Industrial Synthetic Biology Products Products Significant revenue growth in CDMO business; The recogni
Slide 12: Revenue by Customer Category & Region
Revenue by Customer Category & Region Global Revenue by Customer Category Global Revenue by Region Govemment 3% Europe Colleges and 18% University 17% Research 2% The PRC Distributor 20% 3% North America 54% Asia Pacific Phamaceufical (excluding the PRC and Biotech and Japan) Company 5% 75% Others (
Slide 13: Gross Margin Analysis-Segment Performance
Gross Margin Analysis-Segment Performance Gross Profit Gross Profit by Segments 50.0 81.4 41.4 30.4 42.9 100% 32% 14% -33.3% 0.0 100% 1.5 1.0 68% 73% 71% 67% 1H 2017 1H 2018 Bio-science Services and Products Cell Therapy Industrial Synthetic Biology Products Heavy investment in talents for higher
Slide 14: Investment in R&D and Talents for Future Growth
Investment in R&D and Talents for Future Growth R&D Investment(US$ M) Labor Cost Step Up(US$ M) 27.9 18.1 9.5 5.6 7.1 4.8 2014 2015 2016 2017 1H 2017 1H 2018 R&D expenses has risen from 8-12% of group revenue to 25% General Package uplifted US$ 5.7 M; 54 registered patents and 142 pending patent
Slide 15: Business Review
Business Review • BCMA product approved in PRC • Sales made rapid progress and the US, Clinical trial • Production facility optimization progressed as planned • Innovative technology drives • R&D capability well recognized in • GMP facility construction in China significant business Growth for indus
Slide 16: We are the Largest gene synthesis provider
Continuously Enhanced CRO Core Competitiveness We are the Largest gene synthesis provider One of every four synthetic genes is from GenScript Rabbit Monoclonal No.1 Gene Synthesis Globally Combinatorial Library Molecular Cloud Antibodies • Successful delivery of more than • The only CRO company with
Slide 17: Robust CDMO Business Development
Robust CDMO Business Development ADD Sales Order(US$ M) ADD Revenue(US$ M) ADD Backlog(US$ M) 7.15 14.61 17 2.96 4.32 3.51 6.5 5.49 2.27 3.16 H1 2017 H1 2018 H1 2017 H1 2018 1H 2017 1H 2018 Discovery Development Discovery Development The sales order increased by 169% Revenue reached US$ 10.6 mil
Slide 18: CDMO Core Technology Competitiveness
CDMO Core Technology Competitiveness Transmembrane Fully human Target Technology Ab Discovery SMAB FASEBA Remove R&D check point Safety from the start Ab Platform Ab Screening Transmembrane Fully human A platform with Fast and time saving easy development SMAB Bispecific FASEBA We have developed cut
Slide 19: Biologics GMP Facility Roadmap
Biologics GMP Facility Roadmap Estimated GMP Construction Timeline 2019 Q1 2019 Q4 2020 Q1 2021 Q1 2023 Nanjing GMP Scale-up Nanjing cGMP Nanjing cGMP Zhenjiang cGMP Zhenjiang cGMP Phase Production Factory Production Factory Production Factory Production Factory I-III Clinical Production (Nanjing Fa
Slide 20: Multiple Myeloma Market Analysis
Multiple Myeloma Market Analysis Facts about Multiple Myeloma Facts about Current MM Treatment • Serious bone marrow cancer; US$ 29 B • Higher MM incidence rates in Developed countries; US$ 14 B • 7 year survival rate in US is still < 50%; • Velcade and Revlimid remain the backbone therapy across va
Slide 21: 2020 MM Major Market Projection for CAR-T Therapy
2020 MM Major Market Projection for CAR-T Therapy Patient Price Discount Market MKT Share MKT Share MKT Share Region Population EST Rate EST(BN) 30% 50% 70% U.S. 25,000 373,000 100% 9.3 2.8 4.7 6.5 EU5 25,425 279,750 75% 7.1 2.1 3.6 5.0 Japan 5,745 209,813 75% 1.6 0.5 0.8 1.1 Total 56,170 18.0 5.4 9
Slide 22: BCMA CAR-T Progress Update
BCMA CAR-T Progress Update US Clinical Trial Updates China Clinical Trial Updates Phase Overview Phase Overview • Phase: 1b/2 • Phase: Confirmatory Trial • Purpose: Phase 1b to test safety and to determine the dosage of • Purpose: To test safety and efficiency phase 2; Phase 2 to test efficiency Est
Slide 23: Cell Therapy-Pipelines Updates
Cell Therapy-Pipelines Updates Product Candidates Indication Preclinical Phase 1/2 Phase 2/3 LCAR-B38M Multiple Myeloma LCAR-B12L NHL(DLBCL) LCAR-M21L HL LCAR-B12L ALL LCAR-BNA AML LCAR-M12G Gastric Cancer LCAR-B53G GBM LCAR-B16H Undisclosed LCAR-G18C Undisclosed 23
Slide 24: Market Prospects for Current Pipelines
Market Prospects for Current Pipelines Indication Incident Rate Patient Population 2019 Market Size US$ M NHL(≥30) 8.95 345,227 HL(All Age) 1.38 106,461 4,729 AML(≥18) 3.33 179,827 2,579 Gastric Cancer(≥20) 19.96 1,077,881 841 1,122 765 GBM(All Age) 3.57 275,410 NHL HL AML Gastric Cancer GBM The dat
Slide 25: Illustration of Upfront and Milestone payments
Illustration of Upfront and Milestone payments Revenue Recognition of Upfront Payment Milestone Payments Illustration (US$ M) 2017 2018 2019 2020 >>>>>> 2026 Total Revenue 18.4 45.1 35.8 35.8 >>>>>> 35.8 350.0 -License 17.1 9.2 26.4 -Service 1.2 35.8 35.8 35.8 >>>>>> 35.8 323.6 Upfront payment spl
Slide 26: Industrial Synthetic Biology Products-R&D Breakthrough
Industrial Synthetic Biology Products-R&D Breakthrough Enhancement of Sales Force & Network Production Facility Optimization Strengthen sales team Launched a new factory in Jinan with 900 m3 Build up a more solid sales network production capacity Establish long-term partnership with influent
Slide 27: Agenda: Future Strategy
Company Overview Financial & Business Overview Future Strategy Q&A Section Appendix 27
Slide 28: Company Strategy
Company Strategy R&D Production Capacity Global Market Strategic Enhancement Expansion Penetration Acquisition Boost investment in research and Increase production capacity to Deepen our penetration into the Pursue strategic acquisitions and development projects like cell therapy capitalize on the s
Slide 29: Capacity Expansion Strategy
Capacity Expansion Strategy Clinical trail Biologics GMP facilities China CAR-T GMP Facility(Phase 1 ) Total Investment: US$28M Total investment: US$18M CDMO Business 70% of this capital spending absorbed by Commercialization Biologics GMP facilities US CAR-T GMP Facility Total investment:
Slide 30: Global Market Penetration
Global Market Penetration North Europe America Asia Africa The locations of our major operating South subsidiaries: America Nanjing, China Australia Hong Kong New Jersey, US Tokyo, Japan Amsterdam, Netherland Dublin, Ireland Sales Network 30
Slide 31: Investment Highlights
Investment Highlights World Market Strong Sales & Experienced CAR T-Cell Management Leadership Marketing Force Team Therapy We have achieved world market leadership We maintain a strong sales and We have an experienced and Experienced professional team has in gene synthesis services with reputable m
Slide 32: Appendix
Results Highlights Financial & Business Highlights Future Strategy Q&A Section Appendix 32
Slide 33: Appendix
Results Highlights Financial & Business Highlights Future Strategy Q&A Section Appendix 33
Slide 34: Industry Background – Molecular Biology
Industry Background – Molecular Biology Chromosome Cell mRNA Two DNA strands are separated by holoenzyme DNA Base DNA RNA polymerase access to single strand of DNA as a template to synthesize RNA strand Amino acids Peptides tRNA Proteins e.g. Antibody mRNA Peptide chains bends, folds, and twis
Slide 35: Bio-Science Services & Products
Bio-Science Services & Products Life science research services and products Antibody drug discovery and development Services Products Drug Discovery Services Drug Development Services • Gene synthesis • Cloning • Target assessment & validation • Production cell line development • Oligonucleotide syn
Slide 36: Pioneer and Largest Gene Synthesis Supplier in World
Pioneer and Largest Gene Synthesis Supplier in World Multiple Breakthrough IPs and Digital Assets Management Professional Service Assistants Know-how OptimumGeneTM Codon Optimization Successful delivery of more than PhD-level assistants Optimized gene expression 900,000 genes Stronger molecular bi
Slide 37: Antibody Drug Discovery and Development
Antibody Drug Discovery and Development • Gene & Peptide synthesis • Antibody production GMP- Target • Protein production 4 INDs & 1 in Clinical trial • Cell line engineering Compliant Assessment • Crispr KO/KI engineering Manufacturing & Validation • Stable cell line • generation From • Hybridoma d
Slide 38: Industrial Enzymes Business
Industrial Enzymes Business Food Industry Feed Industry Starch Industry Enzymes are used to convert Enzymes improve product quality or Enzymes improve animal feed intake, starch to different kinds of sugars production efficiency for bread, dairy, thereby promoting animal growth such as maltose, fruc
Slide 39: Market Potential For Enzyme Business
Market Potential For Enzyme Business Enzymes Application Enzymes Market Breakdown Technical & Pharma 8% Agriculture & Feed Bioenergy 15% Household Care Bioenergy 33% Feed & Technical & Agriculture Pharma Enzymes Bioenergy 17% Household Food & Care Beverage Food & Beverages 27% Industrial enzyme can
Slide 40: Industrial Enzymes
Industrial Enzymes Gene Synthesis Strain Construction HT Screening Bestzyme has established the Advanced R&D Platform and Up-to-Date Industrialization Transformation Platform in the industry, which covers the entire process from proof of concept, through Refinement Fermentation Application Tests & C
Slide 41: CAR-T Technology Process
CAR-T Technology Process 41
Slide 42: Innovative Design of CAR by Legend
Innovative Design of CAR by Legend All other CAR-T players Nanjing Legend VHH multi-specific CAR BCMA Target A Target B scFv-Conventional CAR VHH-Bi-epitope CAR VHH-multi-specific CAR 42
Slide 43: Sustained Efficacy of LCAR-B38M CAR-T Therapy
Sustained Efficacy of LCAR-B38M CAR-T Therapy Cases as of Total unreported PR VGPR sCR 2017/9/18 response Number 40 1 3 12 24 % 100% 2.5% 7.5% 30% 60% As of 2017/9/18, total 71 patients have been treated, Time since LCAR-B38M CAR-T infusion (Months) 43
Slide 44: LCAR-B38M (cont.)
LCAR-B38M (cont.) Grade 23 adverse event 2 (5.7%) Serious adverse event 0 (0) Fatal events excluding disease progression 0 (0) Cytokine release syndrome (CRS) 60: 17 3S 2 “me PHS -@ PHH2 40. 10 2 ~t PtHS -- PHH8 x 3 - PtH4 + PHHT 20 6 5 —e PHHE PHS 2 > = PHT —- PHO 8 i (0) (e) Oo = Pt#o —— Pt#IO & €
Slide 45: Collaboration between Legend and Janssen
Collaboration between Legend and Janssen On 22 December 2017，Legend Biotech and Janssen Biotech entered into a collaboration and license agreement. • Global co-development, co-production and co-promotion program 关键词 for LCAR-B38M Car-T Cell Immunotherapy Collaboration ; • Legend received an upfront
Slide 46: Thanks
Thanks Genscript Biotech Corporation Make People and Nature Healthier through Biotechnology For More Information：https://www.genscript.com/ IR Contact E-mail：IR@genscript.com